Discover Emerging Technologies in Healthcare [2026 & Beyond]

Executive Summary: 10 Emerging Technologies in Healthcare [2026]

1. Artificial Intelligence (AI) & Machine Learning (ML): AI in healthcare is set to jump to USD 504.2 billion by 2032, with 70% of providers and 80% of payers running AI strategies and 81% of organizations reporting revenue gains.
2. Telehealth & Virtual Care: Telehealth is projected to reach USD 1.21 trillion by 2034. Also, 76% of the US hospitals already connect patients to remote clinicians, and up to USD 250 billion in US care spending is shifting virtual.
3. Internet of Medical Things (IoMT) & Remote Patient Monitoring (RPM): IoMT is tracking toward USD 814.3 billion by 2032. And RPM is growing toward USD 110.7 billion by 2033.
4. Big Data Analytics & Cloud Platforms: Healthcare big data analytics is forecast to grow to USD 327.6 billion by 2034, and cloud hits USD 197.5 billion by 2032.
5. Precision Medicine & Genomics (including Gene Editing): Precision medicine is a board-level priority, with more than 140 000 genetic tests informing care and R&D savings estimated at USD 26 billion annually.
6. Medical & Surgical Robotics: Capital flows of USD 3-3.5 billion highlight scale, with studies showing 10-44% fewer complications vs. lap/open surgery. 78% of surgeons express interest, but only 53% routinely use robots due to cost, training, and workflow hurdles.
7. Digital Therapeutics (DTx) & mHealth: The DTx market is expected to reach USD 32.5 billion by 2034, and mHealth to USD 158 billion by 2030. This market growth is supported by 507 identifiable DTx solutions and large RCT/meta-analysis gains in HbA1c, BP, cholesterol, and adherence.
8. Cybersecurity & Privacy Technologies: Breach costs lead all sectors at USD 10.93 million per incident, encouraging healthcare cybersecurity spending toward USD 75 billion by 2032.
9. 3D Printing & Bioprinting: Healthcare 3D printing is projected to reach USD 27.3 billion by 2030, and bioprinting will grow to USD 4.74 billion by 2033. It is reducing implant lead times from weeks to days and enabling organ-like constructs with defined microarchitecture.
10. Nanotechnology & Nanomedicine: Nanomedicine targets USD 410.2 billion by 2030 with 80+ approved products and expanding LNP pipelines. Also, oncology alone shows 15+ approved nanotherapeutics and 200+ active trials.

How We Researched and Where This Data is From

Analyzed our 3100+ industry reports on innovations to gather relevant insights and create the new technology in the healthcare industry matrix.

Leveraged the StartUs Insights Discovery Platform, an AI and Big Data-powered innovation intelligence platform covering 9M+ emerging companies and over 20K+ technology trends worldwide, to confirm our findings using the trend analysis tool.

Finally, we cross-checked this information with external sources for accuracy.

Frequently Asked Questions (FAQs)

1. What is the most used technology in healthcare?

Electronic health records (EHRs) and broader health information technology (Health IT) are by far the most widely used technologies in healthcare. In the USA, for example, about 85% of office-based physicians utilize EHR technology in various capacities.

2. How is AI used in healthcare?

AI is used across multiple segments of healthcare, including administrative, diagnostic, and predictive-care functions. For example, a 2025 survey found that 58% of provider organizations were using AI for administrative tasks such as medical coding, billing, and scheduling. And 44% deployed AI for clinical decision support or imaging analysis.

Another survey of around 1200 physicians reported that 66% said they used healthcare AI in 2024.

3. What are the main barriers to scaling emerging technologies in healthcare from a business perspective?

Several barriers persist when using emerging technologies in healthcare, like regulatory and governance complexity, infrastructure, data, and interoperability constraints, workflow, and user adoption issues.

4. How can companies measure the ROI of investing in an emerging healthcare technology?

The key steps involve defining objectives such as reducing readmissions and shortening delays. Then, organizations select relevant KPIs like cost savings, improved throughput, and patient experience; account for all direct and indirect costs; and track clinical, operational, and financial benefits over time.

Top 10 Emerging Healthcare Technologies for 2026 & Beyond

1. Artificial Intelligence (AI) and Machine Learning (ML)

Investment: 70% of Healthcare Providers Deploy AI Strategies

The global market for AI in healthcare is projected to grow to about USD 39.25 billion in 2025, with a forecast of reaching USD 504.17 billion by 2032. The market is projected to grow at a CAGR of around 44%.

According to Bain and KLAS research, 70% of providers and 80% of payers have an AI strategy in place or under development. This reflects a sharp rise from the 60% reported the previous year.

For business leaders, these data suggest AI is no longer peripheral but firmly in the investment spotlight that offers large addressable market sizes and investor interest.

Impact: 81% of Healthcare Organizations Report Revenue Growth from AI

AI and ML are influencing multiple vectors of healthcare, such as diagnostics, administrative automation, workflow optimization, population health analytics, and remote monitoring. For example, one study noted that AI-generated operative reports achieved 87.3% accuracy, compared to 72.8% for surgeon-written reports.

According to the WEF, AI addresses global healthcare access gaps affecting 4.5 billion people who lack essential services. It also tackles the projected shortage of 11 million health workers by 2030.

Businesses are already seeing returns. A recent report found that 81% of respondents say AI contributed to increased revenue within their healthcare organization, and nearly half achieved ROI within one year of deployment.

Maturity: 47% of Pharma Firms Cite Data Readiness as the Key Barrier

According to the Bain & Company and Bessemer Venture Partners AI Adoption Index, many healthcare organizations still face major hurdles. These include data readiness, cited by 47% of pharma respondents, along with high integration costs and internal talent gaps.

Also, a global survey by Philips covered over 1900 healthcare professionals and 16 000 patients across 16 countries. It found that clinicians show strong confidence in AI’s ability to deliver better care.

Additionally, Navina offers an AI-driven clinical data analysis platform that enhances decision-making for healthcare providers. In early 2025, it secured a USD 55 million Series C funding round led by Goldman Sachs to expand across 1300 US clinics.

Also, a 2025 rural healthcare study analyzed 109 cases to assess AI’s impact on underserved communities. It found that AI applications, including multimodal foundation models and LLMs, reduced diagnostic delays.

Spotlighting a Startup: Quai.MD

Israeli startup Quai.MD offers an AI- and ML-driven clinical process automation platform that supports physicians in navigating complex patient care. The platform integrates directly with electronic health records (EHRs) to provide real-time, data-informed recommendations embedded within the provider’s workflow.

Its patented AI models combine evidence-based medical knowledge with local patient data to generate personalized diagnostic and treatment pathways tailored to individual clinical scenarios. Moreover, the platform automates physician decisions into actionable processes, produces structured clinical notes for accurate documentation, and optimizes billing efficiency.

For more in-depth insights on AI in healthcare, check out our data-driven report – AI in Healthcare: A Strategic Guide for Industry Leaders [2025-2030].

2. Telehealth and Virtual Care

Investment: Virtual-Care Market Grows Nearly 29% Annually

The global telehealth market is projected at approximately USD 196.8 billion in 2025, with forecasts pointing to USD 1.21 trillion by 2034, representing a CAGR of about 22.6%.

At the same time, the telehealth services segment is projected to grow to USD 71.1 billion in 2025 and then to about USD 505.3 billion by 2034 at a CAGR of 24.3%.

In the US, the virtual-care market is projected to reach about USD 69.2 billion by 2034, with a CAGR of roughly 29.2%.

Impact: 76% of US Hospitals Now Use Telehealth Systems

According to McKinsey, up to USD 250 billion in US healthcare spending could shift to virtual channels, reflecting a structural reallocation of healthcare delivery.

Likewise, the American Hospital Association (AHA) reports that 76% of the US hospitals connect patients with remote clinicians via telehealth systems, compared to just 35% a decade ago.

Global adoption of virtual care is accelerating rapidly. A 2025 study reports that by November 2024, eSanjeevani had facilitated over 276 million teleconsultations.

In the UK, NHS virtual wards allow patients to get the care they need at home, safely and conveniently.

Corporate telehealth networks are scaling cross-border, as seen with Hims & Hers’ acquisition of UK-based ZAVA in 2025.

Maturity: Telehealth Stabilizes at 5% of Medicare Visits Post-Pandemic

During the pandemic, 42% of outpatient visits were done through telehealth. Currently, telehealth accounts for around 5% of all outpatient visits for medicare recipients.

For example, in San Antonio, 22% of adults used telehealth services on a monthly basis. Within this, about 33% of mental health visits occurred virtually in some form.

A 2023 study found 31.3% of primary care visits were made by telephone, 19.5% by video, and 49.2% in person.

However, this maturity curve is steepening as governments and corporations recognize virtual care’s long-term value.

In 2025, Verizon Business signed private 5G and neutral-host network agreements with AdventHealth and Tampa General Hospital.

Spotlighting a Startup: Omniva Telehealth

Indian startup Omniva Telehealth creates a virtual care platform that enables clinics, hospitals, and digital health startups to build and manage telemedicine systems without coding.

The platform integrates secure video and audio consultations, appointment scheduling, digital patient forms, e-prescriptions, and clinical notes within a single interface. It operates through HIPAA-compliant infrastructure to ensure end-to-end encryption and patient data protection across all virtual interactions.

Moreover, its white-label capability allows organizations to customize domains, branding, and user experience to fit their clinical identity. In addition, its mobile apps and patient portals allow patients to book appointments, receive prescriptions, and engage in virtual consultations from anywhere.

For more in-depth insights on telehealth and virtual care, check out our data-driven reports:

• Top 10 Telehealth Trends
• Top 10 Virtual Care Trends

3. Internet of Medical Things (IoMT) and Remote Patient Monitoring (RPM)

Investment: IoMT Market Set to Reach USD 814B by 2032

The global IoMT market is projected to reach USD 814.28 billion by 2032 at a CAGR of 38.5% Meanwhile, the global RPM system market size is projected to reach USD 110.71 billion by 2033, growing at a CAGR of 19.8% from 2025 to 2033.

Alongside the market growth, a 2025 study identified over 2.25 million IoMT devices assessed across 351 healthcare organizations.

Also, security data show a 15% year-over-year rise in the average risk level of IoMT devices.

Patient adoption metrics support investment rationale. For instance, in 2025, 64% of patients reported using at least one IoMT device in daily life, reflecting demand for wearable and remote-monitoring systems.

Impact: RPM Reduces 30-Day Readmissions by Up to 50%

According to a study published in Medical Economics, RPM interventions led to a 50% reduction in 30-day hospital readmissions for heart-failure patients.

A 2024 systematic review found that RPM interventions improved patient safety and enhanced functional status in various care settings.

In hypertension and diabetes care, connected RPM devices enabled near real-time data transmission and early clinical interventions.

Also, about 64% of patients were reported to use at least one IoMT device in their daily lives.

A 2025 report found a 15% year-over-year increase in risk for IoMT devices, highlighting that the impact is not just clinical but operational and risk-driven.

Maturity: 99% of Healthcare Organizations Face IoMT Vulnerabilities

An analysis of more than 2.25 million IoMT devices across 351 healthcare organizations found that 99% of organizations had devices affected by known exploited vulnerabilities.

By 2025, about 71 million Americans, 26% of the population, are projected to use some form of RPM service.

Additionally, academic reviews continue to highlight several persistent hurdles in RPM adoption.

For instance, researchers in Pakistan tested a connected cardiac monitoring IoT framework. The system achieved clinical-grade accuracy in remotely measuring ECG, SpO2, and blood pressure.

Spotlighting a Startup: Healthmonit

Canadian startup Healthmonit provides an IoMT platform that enables continuous RPM through connected healthcare devices and AI-based analytics. Its products include smart IoT devices and a personal monitoring dashboard that captures, stores, and analyzes patient data in real time.

Meanwhile, the monitoring dashboard offers features such as intelligent risk assessment, AI-generated health reports, and smooth integration with healthcare systems.

Additionally, caregivers and physicians use the dashboard to monitor multiple patients, receive alerts, and make timely clinical decisions. The platform’s AI engine interprets patterns, detects potential health risks, and provides personalized recommendations to support proactive care.

4. Big Data Analytics and Cloud Platforms

Investment: Healthcare Cloud & Analytics Investments Surge above USD 60B

The global big data in the healthcare market is projected to reach USD 283.43 billion by 2032 at a CAGR of about 16.78%.

Meanwhile, the global big data analytics in the healthcare market is forecast to grow from about USD 67.32 billion in 2025 to approximately USD 327.57 billion by 2034, at a CAGR of 19.21%.

On the cloud side, the global healthcare cloud-computing market size is projected to grow to USD 63.55 billion in 2025 and reach USD 197.45 billion by 2032 at a CAGR of 17.6%.

Moreover, more than 70% of C-suite executives across five countries said that improving operational efficiencies and productivity gains are priorities for their organizations this year.

Impact: Over 70% of Hospitals Use Cloud for Real-Time Data Sharing

A study found that big data analytics tools are assisting in clinical decision support, population health management, and the innovation of electronic health data flows.

Additionally, one data source shows that by 2024, more than 70% of healthcare institutions will use cloud computing to facilitate real-time data sharing and collaboration.

For instance, Hawai’i Pacific Health (HPH) used a data-driven labor management system and achieved savings of USD 2.2 million over 16 months.

Also, Corewell Health implemented predictive analytics to identify patients at high risk of hospital readmission. The initiative prevented 200 readmissions and generated approximately USD 5 million in savings.

Maturity: Urban Hospitals Reach 90% Analytics Adoption, Rural Below 50%

In 2025, the Dell Medical School at the University of Texas at Austin partnered with Rackspace Technology to migrate its electronic health record (EHR) systems to a private cloud platform.

Similarly, the National Health Service (NHS) adopted the Palantir Technologies Federated Data Platform across 87 acute trusts and 28 integrated care boards.

In the US, large urban hospitals report AI and analytics adoption rates above 80-90%. Additionally, rural facilities remain below 50%, showing that maturity correlates strongly with resource access and infrastructure readiness.

Spotlighting a Startup: Y42

German startup Y42 designs a data orchestration platform that accelerates big data analytics and cloud-native workflows for healthcare organizations. The company connects diverse healthcare data sources into a unified cloud warehouse for the smooth flow of information across systems.

Through its asset-based orchestrator, Y42 ingests, changes, tests, and deploys data pipelines within a single architecture for transparency and consistency throughout the process.

Additionally, its built-in monitoring features provide end-to-end visibility, and Git-based version control allows teams to track both code and data changes efficiently.

5. Precision Medicine and Genomics (including Gene Editing)

Investment: 92% of Pharma Leaders Prioritise Precision Medicine

A survey found that 92% of pharmaceutical industry leaders recognize precision medicine as a strategic opportunity, and 84% have it on their corporate agenda.

It is also estimated that improving R&D via precision medicine might deliver USD 26 billion in annual savings from more efficient drug development.

Venture-capital firm Foresite Capital raised USD 900 million in a life-sciences fund targeting genomics, AI, and precision therapies.

Moreover, in oncology and precision therapeutics, investment in gene editing and genetic profile-based treatments is accelerating.

A 2025 review notes that integrating genomics with multi-omics and AI for precision medicine is becoming a mainstream investment focus.

Additionally, global life sciences firms view genomics-enabled diagnostics and targeted therapies as strategic growth areas, reflected in increasing M&A and platform acquisitions.

Genomic and precision-medicine platforms integrate directly with digital-health and analytics infrastructures.

Impact: 140K+ Genetic Tests Now Guide Clinical Decisions

According to McKinsey, precision medicine moves the healthcare model from one-size-fits-all to the right treatment for the right patient.

A recent research highlights how genomics, transcriptomics, and multi-omics layered within precision medicine enable more accurate disease prediction, personalized interventions, and improved clinical outcomes.

At the same time, precision medicine’s technological ecosystem is expanding through AI-driven innovations. For instance, researchers at Stanford University developed a platform that combines genomics and proteomics to stratify autoimmune-disease patients and design personalized treatment pathways.

In Europe, adoption extends beyond oncology and rare diseases to chronic conditions. This enables genomics-based screening, diagnostics, and long-term disease management.

Additionally, a study found that over 140 000 genetic-based tests are currently being used to guide clinical management decisions.

Precision trial designs in gene editing and targeted therapies are also reducing time-to-market for new drugs and improving trial efficiency through better patient stratification.

Maturity: Genetic Testing Uptake Remains Below 20% Across Europe

A recent review highlights the gap between the promise and practical integration of precision medicine. While next-generation sequencing (NGS) and genomics advance personalized care, challenges persist in data integration, contextual interpretation, and clinical workflows.

Similarly, Adoption reports show that precision-medicine programs continue to expand across health systems.

At the clinical level, more than 140K genetic-based tests are used to inform patient management, yet widespread integration into routine care remains limited. For instance, in Europe, genetic testing for conditions such as familial hypercholesterolemia (FH) remains below 20% uptake in several countries.

Moreover, precision-medicine workflows remain highly IT-intensive; standards like FHIR Genomics, which facilitate interoperable genomic data exchange, are still emerging and unevenly implemented across health systems.

A review of clinical care sites found that institutions with greater precision-medicine maturity, measured by targeted-therapy use and genomic trial enrollment, show stronger integration.

However, many precision-medicine initiatives remain confined to academic and tertiary healthcare systems, limiting broader community-scale diffusion.

Spotlighting a Startup: Gene S

Australian startup Gene S provides a pharmacogenomics (PGx) platform that personalizes medication selection and dosing through advanced genetic testing.

Moreover, its proprietary platform, Rosa, named after Rosalind Franklin, integrates into existing laboratory workflows and delivers results within two to three days.

Using Next Generation Sequencing (NGS) and integrated analytics software, the company analyzes patient DNA to generate detailed pharmacogenomic reports for clinicians to prescribe the right medication at the right dose.

For more in-depth insights on precision medicine and genomics, check out our data-driven reports:

• Top 10 Trends in Precision Medicine
• Top 8 Genomics Trends

6. Medical and Surgical Robotics

Investment: ~USD 3.5B in Global Capital Flowing into Surgical Robotics

According to Bain & Company, investments in surgical robotics reached USD 3-3.5 billion globally in recent years.

The global surgical robots market is projected to reach USD 23.7 billion by 2029, implying a CAGR of 16.5%.

Also, the Asia-Pacific region is expected to grow fastest, driven by government initiatives, rising healthcare infrastructure investment, and the launch of domestic robotics systems. For instance, MicroPort MedBot’s Toumai tele-robotic system achieved global authorization for commercial use in May 2025.

In 2025, Zimmer Biomet announced a definitive agreement to acquire Monogram Technologies for approximately USD 177 million.

Further, in January 2025, surgeons in China successfully conducted a remote robotic surgery over 5000 kilometers via satellite technology.

Impact: Robotic Procedures Reduce Complications by up to 44%

A study found that procedures using the da Vinci system were 10% less likely to experience 30-day postoperative complications than laparoscopy and 44% less likely than open surgery.

Moreover, a review covering major surgical specialties reported fewer surgical site infections, less pain, diminished blood loss, and shorter hospital stays when robotics was used compared with open approaches.

In 2024, the manufacturer reported that 2 683 000 procedures were performed using the da Vinci systems, up about 17% versus the previous year, highlighting rapid scale-up.

Another study in metabolic and bariatric surgery found that the robotic-approach Roux-en-Y gastric bypass reduced operative time from 115.4 minutes to 97.6 minutes and hospital stay from 1.39 days to 1.19 days. It also lowered complication rates from 5.1% to 1.7% compared with laparoscopy.

In thoracic surgery, robotic adoption increased minimally invasive lobectomies from around 40% to about 70%, enabling broader use of less-invasive pathways.

Further, in India, a hospital achieved a milestone of 3544 robotic surgeries as of September 2025, demonstrating regional uptake of the technology.

The expansion of robotics is also offering service-capacity improvements. For example, the National Health Service (UK) aims to raise robot-assisted operations from 70K today to 500K per year by 2035.

Maturity: 53% of Surgeons Actively Use Robotic Platforms

78% of surgeons express interest in robotic-assisted procedures. However, only 53% actively use robotic platforms in practice.

The recently introduced IDEAL Framework for surgical robotics evaluation marks a milestone in maturity. It formalizes clear pathways for safety, effectiveness, and system integration. However, the framework notes that comparative trials, long-term monitoring, and standardized outcomes remain limited in many markets.

Regionally, the maturity gap shows up clearly. Although North America held more than 50% market share in 2024, the Asia-Pacific region is still catching up in terms of infrastructure, training, and reimbursement, which slows full uptake despite high growth potential.

In lower-income and middle-income countries, programs in robotic surgery report pressure from cost, maintenance, and skills-development bottlenecks.

One study noted surgeons needed at least 25 robot-assisted operations to reach comfort with the system setup, loss of tactile feedback, and workflow transitions.

Financially, fragmented reimbursement frameworks and the absence of dedicated procedure codes constrain hospitals’ ability to justify ROI, even when the clinical value is clear.

Spotlighting a Startup: AIRS

South Korean startup AIRS specializes in advanced medical and surgical robotics that combine AI with precision engineering to improve orthopedic and bone-tumor surgery.

The company integrates AI-driven surgical navigation with flexible robotic systems that analyze ultrasound, MRI, and endoscopic images in real time to guide minimally invasive procedures.

Its flagship technologies include the fracture surgery assisting robot system and the bone tumor surgery robot. They improve accuracy and reduce radiation exposure and operation time.

7. Digital Therapeutics (DTx) and mHealth

Investment: DTx Market Expected to Reach USD 20.98B by 2034

The global DTx market is projected to reach USD 32.5 billion by 2030, growing at a CAGR of around 27.77%.

Meanwhile, the global mHealth market is expected to reach USD 158.3 billion by 2030, at a CAGR of about 14.1% between 2024 and 2030.

For example, in the US, the DTx market size is calculated at USD 3.72 billion in 2025, with an expected rise to USD 20.98 billion by 2034.

Also, an industry brief by McKinsey & Company noted that US digital-therapeutic companies have grown on average by 40% a year for the past seven years, in terms of investment.

Digital therapeutics funding jumped by 134% to USD 8.9 billion in recent years as the segment gained attention and scale.

Through the Innovate UK / Eurostars program, my mhealth secured EUR 594 599 in a collaborative bid to scale a DTx solution internationally in 2024.

Additionally, over 507 DTx applications were identified globally in early 2025, with China leading approvals with 235 applications, followed by the US with 192.

Impact: 507 Validated DTx Solutions, 2.5 Billion mHealth Users by 2030

A 2025 review of 393 mHealth studies reported significant clinical improvements, including reduced blood pressure, lower HbA1c in diabetes, improved cholesterol, and enhanced medication adherence.

A randomized field experiment in Asia involving 1070 diabetes patients showed that app users achieved notable HbA1c reductions and increased physical activity.

In diabetes care, one leading DTx provider captured 29.75% of the global market share in 2024.

On the mHealth front, over 50% of the 2023 market revenue came from mobile apps alone, with smartphone penetration expected to rise to 92% by 2030.

AI-driven digital engagement platforms influence behavior at scale. In Singapore, a program with 84 764 participants recorded a 6.17% increase in daily step counts. It also achieved a 7.61% rise in weekly moderate-to-vigorous physical activity (MVPA) over 12 weeks.

Additionally, in rural healthcare, mHealth apps and teleconsultations expand access to medical services for underserved populations.

Maturity: 43% North America Share, 41 Systems Approved, But Reimbursement & Scaling Lag

In 2024, North America captured about 43.9% of the global DTx market share. Meanwhile, although 507 DTx applications were identified across major jurisdictions, many remain in the pilot stage or are limited by local reimbursement models.

A systematic mapping study found that among 365 reviewed papers on mHealth/ubiquitous health systems, data governance and privacy validation remained underrepresented, which is impeding full-scale deployment.

Payer coverage remains a barrier. Until mid-2024, the CMS only proposed reimbursement for digital therapies, signalling that broad payment pathways are not yet established.

Further, in Germany, the DiGA framework (Digitale Gesundheitsanwendungen) had 56 approved digital health applications listed in the directory as of 1 July 2024.

Spotlighting a Startup: MicroHeal

Indian startup MicroHeal offers DTx and mHealth solutions that innovate the management of chronic gastrointestinal (GI) disorders through personalized digital care.

The company combines clinically validated behavioral and nutritional therapy with digital monitoring tools to deliver precision-driven treatment via its application, heal O gut.

The application leverages DTx protocols to address functional gut disorders such as irritable bowel syndrome, functional dyspepsia, and acid reflux. It integrates data from symptom tracking, nutrition logs, and behavioral patterns to personalize treatment.

8. Cybersecurity and Privacy Technologies

Investment: Healthcare Faces the Highest Breach With USD 10.9M Per Incident

The global healthcare cybersecurity spend is projected to be USD 75.0 billion by 2032 at an 18.8% CAGR.

Breach costs remain highest in healthcare at USD 10.93 million per incident, with 213 days to identify. Boards are approving bigger security budgets to reduce dwell time.

After the Change Healthcare attack impacted 192.7 million people in the US, insurers and hospital chains accelerated investments in network segmentation, zero-trust access, and backup orchestration.

Moreover, email remains a major exposure, pushing spending on secure email gateways and DMARC. In H1 2025, 107 attacks compromised 1.6 million records, with Microsoft 365 implicated in 52% of cases.

Ransomware’s share of EU health incidents at 45% and data breaches at 28% is driving European providers to fund immutable backups, MFA, and incident-response retainers.

New mandates also catalyze CapEx and OpEx. The FDA’s 2023-2025 premarket cybersecurity guidance requires SBOMs, vulnerability-management plans, and patch commitments in device submissions.

Impact: 133M Patient Records Exposed in 2023 Breaches

Healthcare led all sectors in 2025 breach cost at USD 10.93 million, prompting shifts toward faster detection and containment in clinical environments.

The 2025 Verizon DBIR analyzed 22 052 incidents and 12 195 breaches, highlighting stolen credentials as dominant in basic web app attacks and supporting identity-centric defenses.

Also, in 2023, providers reported 725 large breaches impacting 133 million records, showing multi-year pressure on PHI protection and vendor-risk programs.

Additionally, EU health remained the most affected critical sector from 2020 to 2023 with 45% ransomware and 28% breach shares, validating endpoint hardening and backup isolation programs.

A major service provider breach exposed 624 000+ identities with SSNs and bank data, illustrating downstream business-associate risk that drives contractual security clauses.

DDoS accounted for 77% of reported EU incidents in 2025, and hospitals increased scrubbing-center subscriptions and API shielding for patient portals.

Email-security failures are linked to 79% lacking effective DMARC, and only 5% phishing reporting rates triggered measurable training and configuration-hardening campaigns.

Maturity: USD 10.93M Average Breach Cost Drives Global Security Upgrades

As NIST CSF 2.0 formalized six core functions plus Govern, many health systems map policies and metrics to Tier targets to mature risk programs.

Moreover, the FDA’s 2023-2025 updates mean cyber-devices must ship with SBOMs, patch plans, and vulnerability monitoring, raising supplier-assurance maturity for connected medical tech.

Nonetheless, EU maturity is uneven. As NIS2 obligations took effect in October 2024, several Member States lag in transposition, forcing cross-border providers to manage mixed compliance states.

Also, since healthcare records have the highest breach costs at USD 10.93 million, boards escalate risk-appetite reviews and fund tabletop exercises to close detection-and-response gaps.

Operationally, email remains weak. 52% of 2025 incidents are tied to Microsoft 365 misconfigurations, so programs now score configuration baselines and quarterly control attestations.

At a macro level, the US providers faced 725 large breaches in 2023 and 739 in 2024.

Likewise, EU health reported a 45% ransomware incident share, so maturity roadmaps now include immutable backups, segmented networks, and quarterly restore tests as board-level KPIs.

Spotlighting a Startup: CyberSalus

US-based startup CyberSalus develops cybersecurity and privacy technologies that safeguard hospitals and healthcare organizations from IoT and medical device vulnerabilities.

The company offers a cybersecurity framework that integrates clinical risk assessment, IoT asset management, and real-time threat monitoring.

Its platform identifies potential risks to sensitive health data and medical networks through continuous ecosystem evaluations and AI-driven analytics.

Moreover, CyberSalus provides vendor-neutral management for IT, IoT, and IoMT assets so that connected devices within healthcare environments remain protected throughout their lifecycle.

9. 3D Printing and Bioprinting

Investment: Market Projected to Reach 18.5% CAGR by 2030

Investors are amplifying capital into 3D printing and bioprinting technologies as healthcare demand for personalized implants and regenerative solutions grows. For example, the global healthcare 3D-printing market is projected to reach USD 27.29 billion by 2030, representing a CAGR of about 18.5% from 2024 to 2030.

Similarly, the global 3D bioprinting market is estimated at USD 3.55 billion in 2025, with a forecast of USD 13.05 billion by 2034, at a CAGR of 15.84%.

On the medical-device side, the global 3D printing-medical devices market is projected to reach USD 6.9 billion by 2028, implying a CAGR of 17.1% in that period.

A review noted that 3D bioprinting intersects with tissue engineering, stem cells, and biomaterials, spurring venture rounds for bio-ink companies and integrated device/print labs.

Additionally, the donor-organ shortage persists. Hence, it is projected that the global 3D bioprinting market could reach USD 8.42 billion by 2034, growing at a 12.54% CAGR from 2025 to 2034.

Impact: 113K Americans Waiting for Transplants Highlight Bioprinting’s Potential

Custom anatomical models improved surgical planning, and early applications enabled surgeons to print exact replicas of a child’s heart, reducing surgical time and improving recovery.

One study demonstrated bioprinted vasculature that is capable of supporting perfusion and cell viability in vitro and highlights translational promise.

A systematic review of 3D bioprinting applications emphasizes that living-cell-enabled constructs may change transplantation, drug testing, and personalized medicine.

Moreover, fabrication efficiency plays a critical role in tissue engineering. One review found that layered bioprinting enables the creation of complex, organ-like structures with defined microarchitecture.

According to MarketsandMarkets, 3D printing of custom implants and devices provides advantages such as shorter time to surgery and reduced intraoperative errors.

From a patient-access perspective, bioprinted constructs reduce dependency on donor organs. With over 113 000 Americans waiting for transplants in 2019, bioprinting offers a solution to address this backlog.

Organovo, for example, demonstrates how printed tissues improve predictive modelling and reduce reliance on animal models.

Maturity: Projected USD 4.74B Market by 2033, but Clinical Translation Still Lagging

On the regulatory front, commercialization of bioprinted tissues encounters hurdles. A study of commercialization challenges lists gene-cell-material complexity, long validation cycles, and reimbursement uncertainty as major barriers.

The inkjet-based bioprinting segment held 35.9% revenue share in 2022, showing technology dominance, but it is also pointing to the limited diversity of mature platforms.

Similarly, one review highlights that although 3D printing is established in models and implants, full regulatory pathways for printed organs or tissues remain nascent.

Additionally, regional disparity persists. Asia-Pacific leads growth in bioprinting, but clinical use and reimbursement lag behind North America and Europe, which limit maturity in those markets.

Further, in hardware adoption, 3D printing labs in hospitals are proliferating, yet fewer major hospitals globally have internal bioprinting capabilities or tissue-print workflows.

Spotlighting a Startup: M3DPRINT

French startup M3DPRINT specializes in 3D printing technology that produces lifelike and functional anatomical models for healthcare applications. The company fabricates high-fidelity replicas of human tissues and organs using precision-engineered materials.

Its 3D printing technology integrates medical imaging data with additive manufacturing. This combination creates patient-specific models that replicate the softness, density, and mechanical behavior of biological structures.

For more in-depth insights, check out our data-driven reports:

• Top 10 3D Printing Trends in Healthcare
• Top 10 Bioprinting Trends in Healthcare

10. Nanotechnology and Nanomedicine

Investment: Market Projected to Grow to USD 410B by 2030 at a 11.6% CAGR

The global nanomedicine market is projected to reach USD 410.15 billion by 2030 at an 11.6% CAGR. It signals sustained capital flows into nano-enabled therapies and vaccines.

Meanwhile, the nanotechnology drug-delivery market is estimated to hit USD 178.32 billion by 2030 at a 10.3% CAGR.

Also, lipid nanoparticles (LNPs), which are critical for mRNA delivery, are projected to grow to USD 2.823 billion by 2032 at a 13.9% CAGR.

Moreover, the FDA’s 2024 guidance on drug products that contain nanomaterials formalizes development expectations and de-risks submissions.

The EMA’s 2025 horizon-scanning for nanotechnology-based medicinal products and reflection papers on liposomes/micelles sharpen EU review pathways.

Additionally, cross-government initiatives via the OECD on nanomaterial safety frameworks reduce policy uncertainty and support scale-up financing.

Moderna projected USD 2.5-3.5 billion in 2025 sales, keeping lipid nanoparticle (LNP) delivery in focus for investors.

Impact: 15+ Cancer Nanomedicines Approved Globally

According to research, there are 15+ approved cancer nanomedicines and 200+ active clinical trials for nano-oncology candidates, evidencing broad therapeutic penetration.

Across indications, 80 nanomedicine products have been approved by the FDA/EMA over the past two decades, confirming clinical translation at scale.

Liposomal drugs alone for 15 FDA-approved products spanning cancer, infections, and pain, anchoring safety/efficacy precedents for newer nano-platforms.

Moreover, first-in-class RNAi therapy Onpattro validated LNP-siRNA delivery for hATTR. It establishes a regulatory and clinical template for gene-silencing nanomedicines.

A 2025 review details market-approved nanoparticle therapeutics and cross-jurisdictional strategies, showing harmonized requirements are enabling global launches.

Additionally, iron oxide nanoparticles improve MRI sensitivity and enable theranostics.

Further, FDA centers and NCTR anticipate a significant increase in nanoscale materials in medical products.

Maturity: 80+ Approved Nanomedicines, 47% Lower Trial Costs, Yet Standardization & Safety Lag

The FDA nanomaterials guidance (2024) documents codify expectations on characterization, quality, and risk management. This improves submission predictability but requires deeper analytics.

Likewise, the EMA 2025 horizon scan plus liposome/micelle reflection papers formalize Europe’s review lens, yet note product-specific complexities that slow one-size-fits-all standards.

Also, safety governance is maturing through OECD nanomaterials programs that advance cross-country risk-assessment toolkits, but long-term ecotox and exposure data remain gaps.

Research indicates health and environmental risk considerations in nanomedicine scale-up. It highlights the need for standardized toxicology endpoints before mass deployment.

Additionally, economic analyses suggest pivotal-trial costs for nanomedicines run at 47% of biologics/NMEs, indicating capital efficiency but also divergent evidence requirements.

Despite multiple approvals, actively targeted cancer nanomedicines remain limited in late-stage development.

Spotlighting a Startup: TechPain

Brazilian startup TechPain creates a nanotechnology-based digital health platform that enhances pain assessment and treatment through real-time monitoring and intelligent data analysis.

The company combines nanotechnology with AI algorithms to capture and interpret physiological signals related to pain.

Its product, TechPain Monitor, is an intuitive mobile application for patients to log symptoms, track emotions, and share updates with clinicians.

Moreover, the TechPain Device is a wearable sensor that collects physiological data from patients undergoing pain treatment and transmits it to the platform for continuous analysis.

Further, the TechPain Device integrates with the TechPain Monitor and TechPain Web to provide healthcare professionals with real-time insights into pain intensity, frequency, and response to therapy.

Explore the Emerging Technologies in Healthcare to Stay Ahead

With emerging technologies reshaping every dimension of healthcare, from diagnostics and treatment to data and delivery, business leaders face the challenge of identifying which innovations will have a significant impact.

As AI, genomics, robotics, and nanotechnology advance toward maturity, success will depend on data-backed strategies that bridge technology, trust, and real-world outcomes.

With access to over 9 million emerging companies and 20K+ technologies & trends globally, our AI and Big Data-powered Discovery Platform equips you with the actionable insights you need to stay ahead of the curve in your market.

Leverage this powerful tool to spot the next big thing before it goes mainstream. Stay relevant, resilient, and ready for what is next.